Allakos Overview

  • Founded
  • 2012
Founded
  • Status
  • Public
  • Employees
  • 141
Employees
  • Stock Symbol
  • ALLK
Stock Symbol
  • Share Price
  • $92.78
  • (As of Monday Closing)

Allakos General Information

Description

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Contact Information

Website
www.allakos.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 975 Island Drive
  • Suite 201
  • Redwood City, CA 94065
  • United States
+1 (650) 000-0000

Allakos Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Allakos Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$92.78 $91.86 $66.01 - $157.98 $4.92B 53.6M 199K -$3.56

Allakos Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 5,481,085 6,938,936 4,132,369 2,007,712
Revenue 0 0 0 0
EBITDA (182,868) (156,248) (90,065) (45,671)
Net Income (181,214) (153,480) (85,372) (43,538)
Total Assets 683,768 719,618 516,894 191,259
Total Debt 45,341 43,265 8,522 123
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Allakos Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Allakos‘s full profile, request access.

Request a free trial

Allakos Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Allakos‘s full profile, request access.

Request a free trial

Allakos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory recep
Drug Delivery
Redwood City, CA
141 As of 2021
00000
000000 - 000 00000

00000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000 0000

o laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
0000 000000000
Boston, MA
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Allakos Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000 000000000000 Venture Capital-Backed Boston, MA 00 000.00 0000000000 0 000.00
00000 00000 000000 Venture Capital-Backed Geneva, Switzerland 00 00000 0000000000 0 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 32 competitors. Get the full list »

Allakos Executive Team (14)

Name Title Board Seat Contact Info
Robert Alexander Ph.D Chief Executive Officer & Board Member
Adam Tomasi Ph.D Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Baird Radford III Chief Financial Officer
Tim Varacek Chief Commercial Officer
Simon Greenwood Ph.D Chief Business Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Allakos Board Members (9)

Name Representing Role Since
Carole Nuechterlein JD Roche Venture Fund Board Observer 000 0000
Daniel Janney Alta Partners Chairman 000 0000
John Mckearn Ph.D RiverVest Venture Partners Board Member 000 0000
Natalie Holles Self Board Member 000 0000
Paul Walker New Enterprise Associates Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Allakos Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allakos Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Allakos‘s full profile, request access.

Request a free trial